Lung and colorectal cancer seem to be most responsive to EGF, which is congruent with the high prevalence of EGFR mutations and overexpression in these indications.50–52 In Fig. 1b we observed that ligand induced proliferation is correlated with treatment response to an antibody targeting the respective receptor. Here, EGFR is linked to colorectal cancer.